Big pharma’s key catalysts in the second quarter
As Biogen heads towards important depression data, Sanofi looks to oncology for growth.
AACR 2021 preview – the early themes emerge
The most important of this year’s two virtual AACRs features immunotherapy combos, new Kras players and first clinical data for several assets.
Wave gets another shot at Huntington’s
The group hopes for a better result with a higher dose of its antisense projects, but it also has a back-up plan.
AD/PD 2021 – Donanemab has much still to prove
Full data on Lilly's Alzheimer’s antibody will disappoint some, and point to a long road ahead.
Lilly lines up its next shot at Alzheimer’s
Expectations are high ahead of a detailed look at donanemab data, but hopes for a fast path to market feel overblown.
A busy year ahead for Parkinson’s disease
As several big pharma companies drop Parkinson’s projects, attention turns to gene therapies and repurposing diabetes drugs.
Go or no go? A delayed decision on Evrenzo
March will see big US decisions for Evrenzo and ide-cel, while tanezumab goes in front of an advisory committee.
Biocryst looks to raise the profile of its factor D inhibitor
The relatively low-key asset might at least partly be responsible for Biocryst shares more than doubling since the start of December.
Asco-GU – Clear blue water between Keytruda and kidney cancer rivals
Merck & Co/Eisai’s Clear study results look better than Bristol/Exelixis’s Checkmate-9ER, but the big loser could be Pfizer.
